William Garner

Dr William Garner is a US physician, investor and entrepreneur. Dr Garner is one of the inventors on the Bisantrene patents, originally filed by Update Pharma and now owned by Race Oncology. Previously, he founded EGB Advisors LLC, a life sciences advisory firm whose clients have included the MD Anderson Cancer Center, the Kauffman Foundation, ChemGenex (ASX:CXS) and CoTherix. He also founded Inverseon which was merged with the ASX-listed company cBio to create Invion, serving as chief executive until May of 2013. He founded Urigen Pharmaceuticals and co-founded DelMar Pharmaceuticals (NASDAQ:DMPI). Previously, he was at Hoffmann La Roche in oncology medical affairs and worked as a merchant banker in New York City. Dr Garner is chair of InMed Pharmaceuticals (CSE:IN, OCTQB:IMLFF) & Isla Pharmaceuticals, and works with several of the other portfolio companies of EGB Ventures. Dr Garner has a Master of Public Health from Harvard and received his MD degree from New York Medical College. Dr Garner did residency training in Anatomic Pathology at Columbia-Presbyterian and is a licensed physician in the State of New York.
Bio last updated 16 May 2018

Access to our data for William Garner is only available to paid subscribers with access.

The search engine is Western Australia's most accurate and comprehensive business listings and searchable database.

William Garner is linked to 1 organisation which is included in 1 list - Public Companies - Industrial.

To see the data you will need to .

Total Shareholder Return as at 31/10/18

1 year TSR5 year TSR
127thQueste Communications40%-4%
480thG Medical Innovations Holdings-20%0%
777thRace Oncology-66%0%
744 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar


Non-Executive Chairman
Year started and most recent title


193rd↓Queste Communications$172k
194th-Race Oncology$170k
195th↓Oakajee Corporation$158k
196th↑G Medical Innovations Holdings$140k
239 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer